logo
Plus   Neg
Share
Email

Harris Q4 Profit Surges - Quick Facts

Harris Corp.'s (HRS) fourth-quarter net income attributable to the company jumped to $131.4 million or $1.22 per share from $55.5 million or $0.51 per share, last year.

The company's GAAP income from continuing operations totaled $138 million, or $1.28 per share, versus $71 million, or $0.65 per share, a year ago. Prior year non-GAAP income from continuing operations, excluding charges related to restructuring and other actions, was $154 million, or $1.41 per share. On average, 10 analysts polled by Thomson Reuters expected earnings per share of $1.28 for the quarter. Analysts' estimates typically exclude one-time items.

The firm clocked $1.33 billion in revenue for the latest quarter, compared with the prior-year figure of $1.36 billion, while 9 analysts estimated revenues of $1.30 billion.

For fiscal 2015, the company's initial guidance for GAAP income from continuing operations is in a range of $4.75 to $5.00 per share. Revenue guidance for fiscal 2015 is a range of 1 to 3 percent lower compared with fiscal 2014.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT